Expert guides on insurance appeals, denial management, and prior authorization for billing professionals and healthcare providers.
CPT J3490 (Unclassified Drug (Specialty Pharmacy)) denied by Aetna? ~15-20% estimated based on marketplace data. Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J3490 (Unclassified Drug (Specialty Pharmacy)) denied by Blue Cross Blue Shield? Varies by affiliate; BCBS Alabama reported 35% denial rate (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J3490 (Unclassified Drug (Specialty Pharmacy)) denied by UnitedHealthcare? 33% in-network denial rate on HealthCare.gov plans (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J1745 (Infliximab (Remicade) Infusion) denied by Molina Healthcare? 26% in-network denial rate on HealthCare.gov (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J1745 (Infliximab (Remicade) Infusion) denied by Anthem (Elevance Health)? 23% in-network denial rate on HealthCare.gov (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J1745 (Infliximab (Remicade) Infusion) denied by Medicare (Traditional)? 7.38% improper payment rate (FFS). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J1745 (Infliximab (Remicade) Infusion) denied by Humana? ~17% for Medicare Advantage initial denials. Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J1745 (Infliximab (Remicade) Infusion) denied by Cigna? ~15-18% estimated based on marketplace data. Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J1745 (Infliximab (Remicade) Infusion) denied by Aetna? ~15-20% estimated based on marketplace data. Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J1745 (Infliximab (Remicade) Infusion) denied by Blue Cross Blue Shield? Varies by affiliate; BCBS Alabama reported 35% denial rate (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J1745 (Infliximab (Remicade) Infusion) denied by UnitedHealthcare? 33% in-network denial rate on HealthCare.gov plans (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J0585 (Botulinum Toxin Type A (Botox)) denied by Molina Healthcare? 26% in-network denial rate on HealthCare.gov (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J0585 (Botulinum Toxin Type A (Botox)) denied by Anthem (Elevance Health)? 23% in-network denial rate on HealthCare.gov (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J0585 (Botulinum Toxin Type A (Botox)) denied by Medicare (Traditional)? 7.38% improper payment rate (FFS). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J0585 (Botulinum Toxin Type A (Botox)) denied by Humana? ~17% for Medicare Advantage initial denials. Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J0585 (Botulinum Toxin Type A (Botox)) denied by Cigna? ~15-18% estimated based on marketplace data. Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J0585 (Botulinum Toxin Type A (Botox)) denied by Aetna? ~15-20% estimated based on marketplace data. Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J0585 (Botulinum Toxin Type A (Botox)) denied by Blue Cross Blue Shield? Varies by affiliate; BCBS Alabama reported 35% denial rate (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT J0585 (Botulinum Toxin Type A (Botox)) denied by UnitedHealthcare? 33% in-network denial rate on HealthCare.gov plans (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
CPT G0155 (Home Health Social Work Visit) denied by Molina Healthcare? 26% in-network denial rate on HealthCare.gov (2023). Less than 1% of patients appeal — but 44% of appealed denials are overturned at internal appeal. Step-by-step appeal guide with letter template.
EZAppeal generates payer-specific appeal letters in 60 seconds. Generate your first appeal — free →